{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:13:31Z","timestamp":1788455611474,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jhepr.2023.100956","type":"journal-article","created":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T03:50:38Z","timestamp":1699069838000},"page":"100956","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["HBcrAg-based risk score performs better than the HBV DNA-based scores for HCC prediction in grey zone patients who are HBeAg-negative"],"prefix":"10.1016","volume":"6","author":[{"given":"Tai-Chung","family":"Tseng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Hosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Jen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5232-796X","authenticated-orcid":false,"given":"Fumitaka","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4319-4565","authenticated-orcid":false,"given":"Chieh","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0075-1280","authenticated-orcid":false,"given":"Chun-Ming","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromitsu","family":"Kumada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6254-4383","authenticated-orcid":false,"given":"Wan-Ting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6747-7941","authenticated-orcid":false,"given":"Tung-Hung","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Chih","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3622-9707","authenticated-orcid":false,"given":"Chen-Hua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Jer","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2442-7952","authenticated-orcid":false,"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2023.100956_bib1","doi-asserted-by":"crossref","first-page":"e00046","DOI":"10.1128\/CMR.00046-19","article-title":"Hepatitis B virus: advances in prevention, diagnosis, and therapy","volume":"33","author":"Nguyen","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jhepr.2023.100956_bib2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12916-017-0820-x","article-title":"Elimination of hepatitis B: is it a mission possible?","volume":"15","author":"Tseng","year":"2017","journal-title":"BMC Med"},{"key":"10.1016\/j.jhepr.2023.100956_bib3","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1055\/s-0041-1730924","article-title":"Application of risk scores for hepatocellular carcinoma in patients with chronic hepatitis B: current status and future perspective","volume":"41","author":"Hsu","year":"2021","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhepr.2023.100956_bib4","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/jvh.12643","article-title":"Determination of hepatitis B phenotype using biochemical and serological markers","volume":"24","author":"Di Bisceglie","year":"2017","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhepr.2023.100956_bib5","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.cgh.2021.01.019","article-title":"Natural history and hepatocellular carcinoma risk in untreated chronic hepatitis B patients with indeterminate phase","volume":"20","author":"Huang","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2023.100956_bib6","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.14309\/ajg.0000000000000400","article-title":"Phase transition is infrequent among North American adults with e-antigen-negative chronic hepatitis B and low-level viremia","volume":"114","author":"Zhou","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2023.100956_bib7","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1111\/apt.14613","article-title":"Anti-viral therapy can be delayed or avoided in a significant proportion of HBeAg-negative Caucasian patients in the grey zone","volume":"47","author":"Bonacci","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2023.100956_bib8","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1016\/j.cgh.2019.01.002","article-title":"Progression of untreated minimally active chronic HBV infection compared to inactive infection","volume":"17","author":"Lee","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2023.100956_bib9","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/liv.13346","article-title":"Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA","volume":"37","author":"Wong","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2023.100956_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/jmv.21339","article-title":"Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients","volume":"81","author":"Suzuki","year":"2009","journal-title":"J Med Virol"},{"key":"10.1016\/j.jhepr.2023.100956_bib11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJMra2211764","article-title":"New approaches to chronic hepatitis B","volume":"388","author":"Dusheiko","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2023.100956_bib12","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1053\/j.gastro.2019.08.028","article-title":"High level of hepatitis B core-related antigen associated with increased risk of hepatocellular carcinoma in patients with chronic HBV infection of intermediate viral load","volume":"157","author":"Tseng","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2023.100956_bib13","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1111\/jvh.13191","article-title":"Hepatitis B core-related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinoma","volume":"26","author":"To","year":"2019","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhepr.2023.100956_bib14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jhep.2016.03.013","article-title":"HBcrAg predicts hepatocellular carcinoma development: an analysis using time-dependent receiver operating characteristics","volume":"65","author":"Tada","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2023.100956_bib15","doi-asserted-by":"crossref","first-page":"748","DOI":"10.14309\/ajg.0000000000001691","article-title":"Hepatitis B core-related antigen stratifies the risk of liver cancer in HBeAg-negative patients with indeterminate phase","volume":"117","author":"Tseng","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2023.100956_bib16","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1470-2045(11)70077-8","article-title":"Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score","volume":"12","author":"Yang","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2023.100956_bib17","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jhep.2008.07.023","article-title":"Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B","volume":"50","author":"Yuen","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2023.100956_bib18","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1200\/JCO.2009.26.2675","article-title":"Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers","volume":"28","author":"Wong","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhepr.2023.100956_bib19","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/ajg.2017.254","article-title":"Fibrosis-4 index helps identify HBV carriers with the lowest risk of hepatocellular carcinoma","volume":"112","author":"Tseng","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2023.100956_bib20","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2012.02.007","article-title":"High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load","volume":"142","author":"Tseng","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2023.100956_bib21","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/apt.16266","article-title":"Serum hepatitis B core-related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load","volume":"53","author":"Tseng","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2023.100956_bib22","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/hep.26041","article-title":"Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads","volume":"57","author":"Tseng","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2023.100956_bib23","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1053\/j.gastro.2011.04.046","article-title":"Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters","volume":"141","author":"Tseng","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2023.100956_bib24","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/hep.24615","article-title":"Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load","volume":"55","author":"Tseng","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2023.100956_bib25","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2023.100956_bib26","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1136\/gutjnl-2014-306977","article-title":"Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers","volume":"64","author":"Tseng","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2023.100956_bib27","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.jhep.2020.01.012","article-title":"HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis","volume":"72","author":"Tseng","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2023.100956_bib28","series-title":"Regression modeling strategies: with applications to linear\u00a0models, logistic regression, and survival analysis","author":"Harrell","year":"2001"},{"key":"10.1016\/j.jhepr.2023.100956_bib29","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/apt.15725","article-title":"Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients","volume":"51","author":"Kim","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2023.100956_bib30","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/sim.4154","article-title":"On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data","volume":"30","author":"Uno","year":"2011","journal-title":"Stat Med"},{"key":"10.1016\/j.jhepr.2023.100956_bib31","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.cgh.2020.04.091","article-title":"Should treatment indications for chronic hepatitis B be expanded?","volume":"19","author":"Jeng","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2023.100956_bib32","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S1473-3099(20)30692-7","article-title":"Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase (TORCH-B): a multicentre, double-blind, placebo-controlled, parallel-group, randomised trial","volume":"21","author":"Hsu","year":"2021","journal-title":"Lancet Infect Dis"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555923002872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555923002872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T09:59:34Z","timestamp":1716285574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555923002872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2589555923002872"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2023.100956","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HBcrAg-based risk score performs better than the HBV DNA-based scores for HCC prediction in grey zone patients who are HBeAg-negative","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2023.100956","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"100956"}}